A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Public ClinicalTrials.gov record NCT01053988. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Study identification
- NCT ID
- NCT01053988
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 1,031 participants
Conditions and interventions
Conditions
Interventions
- FF/GW642444 Inhalation Powder Drug
- FF Inhalation Powder Drug
- GW642444 Inhalation Powder Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2009
- Primary completion
- Jan 31, 2011
- Completion
- Apr 13, 2011
- Last update posted
- Jul 11, 2018
2009 – 2011
United States locations
- U.S. sites
- 47
- U.S. states
- 20
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Mobile | Alabama | 36608 | — |
| GSK Investigational Site | Montgomery | Alabama | 36106 | — |
| GSK Investigational Site | Phoenix | Arizona | 85032 | — |
| GSK Investigational Site | Scottsdale | Arizona | 85258 | — |
| GSK Investigational Site | Encinitas | California | 92024 | — |
| GSK Investigational Site | Rancho Mirage | California | 92270 | — |
| GSK Investigational Site | Riverside | California | 92506 | — |
| GSK Investigational Site | San Diego | California | 92117 | — |
| GSK Investigational Site | Sepulveda | California | 91343 | — |
| GSK Investigational Site | Clearwater | Florida | 33755 | — |
| GSK Investigational Site | DeLand | Florida | 32720 | — |
| GSK Investigational Site | Maitland | Florida | 32751 | — |
| GSK Investigational Site | Miami | Florida | 33125 | — |
| GSK Investigational Site | Orlando | Florida | 32822 | — |
| GSK Investigational Site | Panama City | Florida | 32405 | — |
| GSK Investigational Site | Tamarac | Florida | 33321 | — |
| GSK Investigational Site | Winter Park | Florida | 32789 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Austell | Georgia | 30106 | — |
| GSK Investigational Site | Marietta | Georgia | 30060 | — |
| GSK Investigational Site | Stockbridge | Georgia | 30281 | — |
| GSK Investigational Site | Coeur d'Alene | Idaho | 83814 | — |
| GSK Investigational Site | Evansville | Indiana | 47714 | — |
| GSK Investigational Site | Wichita | Kansas | 67205 | — |
| GSK Investigational Site | Wichita | Kansas | 67207 | — |
| GSK Investigational Site | Hazard | Kentucky | 41701 | — |
| GSK Investigational Site | Madisonville | Kentucky | 42431 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70115 | — |
| GSK Investigational Site | Sunset | Louisiana | 70584 | — |
| GSK Investigational Site | Baltimore | Maryland | 21224 | — |
| GSK Investigational Site | Fall River | Massachusetts | 02720 | — |
| GSK Investigational Site | Livonia | Michigan | 48152 | — |
| GSK Investigational Site | Edina | Minnesota | 55438 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55407 | — |
| GSK Investigational Site | St Louis | Missouri | 63117 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28207 | — |
| GSK Investigational Site | Wilmington | North Carolina | 28401 | — |
| GSK Investigational Site | Columbus | Ohio | 43215 | — |
| GSK Investigational Site | Medford | Oregon | 97504 | — |
| GSK Investigational Site | Charleston | South Carolina | 29406-7108 | — |
| GSK Investigational Site | Gaffney | South Carolina | 29340 | — |
| GSK Investigational Site | Greenville | South Carolina | 29615 | — |
| GSK Investigational Site | Pelzer | South Carolina | 29669 | — |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Wichita Falls | Texas | 76309 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01053988, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2018 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01053988 live on ClinicalTrials.gov.